Compare GVH & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GVH | KPRX |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 11.7M |
| IPO Year | 2023 | 2014 |
| Metric | GVH | KPRX |
|---|---|---|
| Price | $1.01 | $2.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $80.00 | $10.00 |
| AVG Volume (30 Days) | ★ 1.1M | 21.1K |
| Earning Date | 02-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102,768.97 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $1.76 |
| 52 Week High | $6.46 | $2.99 |
| Indicator | GVH | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.11 | 43.81 |
| Support Level | $0.87 | $2.43 |
| Resistance Level | $1.29 | $2.61 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 29.97 | 30.43 |
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.